More on GSK's Depemokimab Development Plans Earlier this year, two phase III studies namely — SWIFT-1 and SWIFT-2 — which evaluated depemokimab for treating severe asthma characterized by type ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

Depemokimab's twice-yearly dosing regimen could offer a new approach to managing this chronic condition. With annual revenues of $39.28 billion and a steady dividend yield of 4.18%, GSK ...

GSK) is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK ranks 1st on our list of most undervalued healthcare stocks to ...

GSK plc GSK announced that the FDA has approved ... Other planned launches include Blenrep (for multiple myeloma), depemokimab (chronic rhinosinusitis with nasal polyps and asthma with type ...